To include your compound in the COVID-19 Resource Center, submit it here.

Safety first

Safety data enabled antibiotics play VenatoRx to attract institutional investors

Phase I safety data for VNRX-5133 enabled VenatoRx Pharmaceuticals Inc. to bring its first institutional investors on board for a $42 million series B round.

Versant Ventures led the tranched round on July

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers